A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation.

A series of 6- or 7-substituted 2-carboxamido- or 2-(aminomethyl)-1,4-benzodioxin and -2,3-dihydro-1,4-benzodioxin derivatives were synthesized and evaluated to determine the necessary structural requirements for a high inhibition of human low-density lipoprotein copper-induced peroxidation. The most active compounds (21, 25, 28, 36, and 37) were found between 5 and >45 times more active than probucol itself. Due to both their potency and their structural features, compounds 25 and 36 were selected with others for complementary in vitro and in vivo investigations. Both of them exhibit calcium antagonist properties in the same range of potency as flunarizine itself. Compound 36 was also found to have significant hypolipaemic activity in mice at 100 and 300 mg/kg po, while compound 25 proved to be clearly active in a normobar hypoxia test.

DNA interaction and cytotoxicity of a new series of indolo[2,3-b]quinoxaline and pyridopyrazino[2,3-b]indole derivatives.

Absorption, melting temperature and linear dichroism measurements were performed to investigate the interaction with DNA of a series of 16 tricyclic and tetracyclic compounds related to the antiviral agent B-220. The relative DNA affinity of the test compounds containing an indolo[2,3-b]quinoxaline, pyridopyrazino[2,3-b]indoles or pyrazino[2,3-b]indole planar chromophore varies significantly depending on the nature of the side chain grafted onto the indole nitrogen. Compounds with a dimethylaminoethyl chain strongly bind to DNA and exhibit a preference for GC-rich DNA sequences, as revealed by DNase I footprinting. Weaker DNA interactions were detected with those bearing a morpholinoethyl side chain. The incorporation of a 2,3-dihydroxypropyl side chain does not reinforce the DNA interaction compared with the unsubstituted analogues. Both the DNA relaxation assay and cytotoxicity study using two human leukemia cell lines sensitive (HL-60) or resistant (HL-60/MX2) to the antitumor drug mitoxantrone, indicate that topoisomerase II is not a privileged target for the test compounds which only weakly interfere with the catalytic activity of the DNA cleaving enzyme. Cytometry studies showed that the most cytotoxic compounds induce a massive accumulation of cells in the G2/M phase of the cell cycle. Collectively, the data show a relationship between DNA binding and cytotoxicity in the indolo[2,3-b]quinoxaline series.

Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (I).

The synthesis of a new series of alpha- and beta-adrenergic blocking agents 14 is described. The affinity and selectivity of these compounds for alpha, beta 1 and beta 2-adrenoceptors were studied in comparison with those of WB-4101 and propranolol. The derivatives 14cx and 14dx are more potent beta 1-blockers than propranolol.

Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (II).

The four stereoisomers of compound 1 were synthesized from 2,3-dihydro-1, 4-benzodioxin and evaluated as alpha- and beta-adrenergic antagonists. Enantiomer 1-b [2R, 2'S] (Figure 1) is the best beta 1-blocking agent. Furthermore all compounds showed a alpha-blocking activity.

Biophysical and biological properties of newly synthesized dioxinocoumarin derivatives. II. Dark and photoinduced effects on T7 phage, yeast and HeLa cells.

The dioxinocoumarin derivatives 5H-[2]benzopyrano-[3,4-g][1,4]benzodioxin-5-one (I), 5H-[2]benzopyrano-[3,4-g][2,3]-dihydro-[1,4]benzodioxin-5-on e II, 6H-[2]benzopyrano[3,4-f]-1,4-benzodioxin-6-one (III) and 6H-[2]benzopyrano[3,4-f]-2,3-dihydro-1,4-benzodioxin-6-one (IV) were synthesized. Their biological effect was studied in the presence and absence of UVA radiation, and compared with that of 8-methoxypsoralen (8-MOP) and angelicin derivatives on T7 phage, diploid yeast (Saccharomyces cerevisiae) and HeLa cells. The photobiological activities of compounds I and III were stronger than that of 8-MOP in phage inactivation and DNA synthesis inhibition in HeLa cells, whereas compounds II and IV, with a saturated dioxin ring, showed very poor activity. The photosensitizing activity of dioxinocoumarins on phage inactivation decreased by a factor of two to three in the absence of oxygen. Treatments with compound I and UVA in the presence of oxygen modified the helical structure and stability of phage DNA and proteins. Compounds I and II were more active than IV for photoinduced cell killing in yeast, although always less active than 8-MOP. At comparable photocytotoxic levels, compounds I and III were as strong inducers of cytoplasmic "petite" mutants in yeast as angelicin, suggesting a possible monofunctional mode of action with cellular DNA.

Biophysical and biological properties of newly synthesized dioxinocoumarin derivatives. Part I: Dark effects on T7 phage and HeLa cells.

Several dioxinocoumarin derivatives have been synthesized for photochemotherapeutical purposes. The physicochemical properties of 3,4-benzo-6,7-dioxinocoumarin and its biological activity in the dark were studied with regard to future photobiological applications. It was found that molecular aggregates are formed in aqueous solution at a concentration higher than 10(-5) mol l-1. In the dark, 3,4-benzo-6,7-dioxinocoumarin inactivates T7 phage and inhibits the growth of HeLa cells in a concentration-dependent manner. The dark inactivation of T7 phage was quantitatively characterized. It was found to be higher than that of 8-methoxypsoralen (8-MOP) and approximately equal to 4,6,4'-trimethylangelicin (TMA). From the inactivation kinetics and the lack of a quenching effect of polynucleotides on the fluorescence emission of the drug, it appears that, apart from the induction of DNA damage, other events are implicated in T7 phage dark inactivation. These results are important for the interpretation of the photobiological effects of this type of compound.

Enzyme immunoassay for flecainide.

In order to develop an enzyme immunoassay (ELISA) for measurement of plasma flecainide levels, we first synthesized flecainide-hemisuccinate-BSA as immunogen. A highly specific antiserum was then raised in rabbits. Enzyme-labelled flecainide was prepared by the mixed anhydride method using hemifumarate-flecainide and horse radish peroxidase. The limit of detection was 10 ng/ml, the method was linear up to 1,000 micrograms/l. The intra and inter-assay variation was 5.1-7.8%. Cross reactivity with various metabolites of flecainide or some chemically related drugs was less than 0.1%. By contrast the cross reaction with some structural analogues achieved 25%. The importance of parts of the aromatic ring structure in immunogenic properties of this drug is discussed.

2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.

Various 2-benzodioxinylaminoethanol derivatives were synthetized and investigated for beta-adrenergic blocking activity. Most compounds demonstrated a beta-blocking activity of a competitive type when evaluated in guinea pig atrial and tracheal preparations. Three compounds were more potent than practolol and propranolol. All compounds demonstrated antihypertensive properties in spontaneously hypertensive rats. The most active compound was 1-(1,4-benzodioxin-2-yl)-2-[N4-(2-methoxyphenyl)piperazino]ethanol (11), which at 2.5 mg/kg iv lowered blood pressure by 41%.